SLC5A2 and type 2 diabetes mellitus: The EXAMINE trial was published in 2013, a time where therapies that improve cardiovascular outcomes of patients with type 2 diabetes (e.g., SGLT2 inhibitors and GLP1 receptor agonists) where not available yet; therefore, our findings may not be applicable to more contemporary cohorts.